Dr. Katie R Evans, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 616 9th St N, Virginia, MN 55792 Phone: 218-749-3818 Fax: 218-749-3874 |
Range Podiatric Care, Pa Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 809 N 6th Ave, Northgate Plaza, Virginia, MN 55792 Phone: 218-749-3818 Fax: 218-749-3874 |
Range Foot & Ankle, Plc Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 616 9th St N, Virginia, MN 55792 Phone: 218-749-3818 Fax: 218-749-3874 |
Andrew Mekhail Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 1101 9th St N, Virginia, MN 55792 Phone: 218-305-0201 |
News Archive
The GW School of Medicine and Health Sciences is pleased to announce the establishment of the Office of Clinical Practice Innovation. The new office will serve as the organizational home for developing and evaluating clinical interventions to improve medical care.
The increasing popularity and availability of e-cigarettes (otherwise known as Electronic Nicotine Delivery Systems, or ENDS) in many countries has prompted fierce debate among public health professionals, with some expressing concerns that lack of safety information for the devices could result in unforeseen damage to public health if they are not appropriately regulated.
A UK study in this week's issue of THE LANCET suggests that reliance on published studies alone to guide the treatment of childhood depression could be inappropriate. A systematic review including published and unpublished data shows that only one drug, fluoxetine (Prozac), was not associated with negative outcomes for children with depression.
Researchers have identified a rare genetic syndrome characterized by intellectual disability, seizures, an abnormal gait and distinctive facial features.
After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
› Verified 3 days ago